MRK · 10-Q · 2026Q3 · Full report
WINREVAIR Demand Growth
Merck & Co., Inc. · 2026-11-04 · Importance 59 · Surprise 64 · In source text
Winrevair sales rose 93% in the third quarter and 85% in the first nine months of 2026, largely reflecting higher demand and launch uptake in international markets. U.S. wholesaler and specialty pharmacy purchase timing also benefited quarterly and year-to-date sales, with that effect expected to unwind in the fourth quarter. International uptake was particularly evident in Europe and Japan, where the product is marketed as Airwin. Winrevair is indicated for adults with pulmonary arterial hypertension and received expanded-indication approvals in the EU and U.S.
Key facts
- Winrevair sales rose 93% in Q3 2026 and 85% in the first nine months, driven largely by higher demand, U.S. purchase timing and international launch uptake, particularly Europe and Japan. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Winrevair sales rose 93% in Q3 2026 and 85% in the first nine months, driven largely by higher demand, U.S. purchase timing and… |